Research analysts covering CS DIAGNOSTICS.
Recent press releases and 8-K filings for CSDX.
CS Diagnostics Corp. Completes Preferred Share Conversion for Consolidated Financial Reporting
CSDX
Accounting Changes
Capital Structure Change
- CS Diagnostics Corp. (CSDX) announced on October 31, 2025, that its affiliate companies, CS Interpharm and CS Diagnostics Pharma, completed the conversion of their Series B Preferred Stock into 112,652,000 shares of common stock on October 30, 2025.
- This strategic conversion aims to simplify CSDX's equity capitalization and enable consolidated financial reporting across all affiliated entities by fiscal year-end, December 31, 2025.
- The company expects this move to lead to enhanced transparency, improved efficiency, and a stronger capital market position, fostering greater alignment among all shareholders.
Oct 31, 2025, 6:11 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more